BioMarin Pharmaceutical, Inc. (BMRN)
57.33
+0.83
(+1.47%)
USD |
NASDAQ |
Jun 24, 16:00
57.52
+0.19
(+0.33%)
After-Hours: 04:56
BioMarin Pharmaceutical Accounts Receivable (Quarterly) : 903.91M for March 31, 2026
Accounts Receivable (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Accounts Receivable (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 903.91M |
| December 31, 2025 | 908.21M |
| September 30, 2025 | 790.27M |
| June 30, 2025 | 855.86M |
| March 31, 2025 | 739.18M |
| December 31, 2024 | 660.54M |
| September 30, 2024 | 777.55M |
| June 30, 2024 | 691.23M |
| March 31, 2024 | 637.16M |
| December 31, 2023 | 633.70M |
| September 30, 2023 | 572.50M |
| June 30, 2023 | 610.22M |
| March 31, 2023 | 597.91M |
| December 31, 2022 | 461.32M |
| September 30, 2022 | 419.62M |
| June 30, 2022 | 466.51M |
| March 31, 2022 | 430.15M |
| December 31, 2021 | 373.40M |
| September 30, 2021 | 374.94M |
| June 30, 2021 | 424.42M |
| March 31, 2021 | 396.10M |
| December 31, 2020 | 448.35M |
| September 30, 2020 | 411.71M |
| June 30, 2020 | 381.22M |
| March 31, 2020 | 396.38M |
| Date | Value |
|---|---|
| December 31, 2019 | 377.40M |
| September 30, 2019 | 402.97M |
| June 30, 2019 | 377.15M |
| March 31, 2019 | 393.43M |
| December 31, 2018 | 342.63M |
| September 30, 2018 | 384.34M |
| June 30, 2018 | 363.57M |
| March 31, 2018 | 318.39M |
| December 31, 2017 | 261.36M |
| September 30, 2017 | 251.89M |
| June 30, 2017 | 238.34M |
| March 31, 2017 | 230.25M |
| December 31, 2016 | 215.28M |
| September 30, 2016 | 215.89M |
| June 30, 2016 | 214.16M |
| March 31, 2016 | 180.75M |
| December 31, 2015 | 164.96M |
| September 30, 2015 | 125.05M |
| June 30, 2015 | 159.18M |
| March 31, 2015 | 145.54M |
| December 31, 2014 | 144.47M |
| September 30, 2014 | 121.40M |
| June 30, 2014 | 122.28M |
| March 31, 2014 | 110.46M |
| December 31, 2013 | 117.82M |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Accounts Receivable (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 883.96M |
| Incyte Corp. | 1.051B |
| Ionis Pharmaceuticals, Inc. | 73.68M |
| Cytokinetics, Inc. | 6.827M |
| Regeneron Pharmaceuticals, Inc. | 5.731B |